Filgrastim

證據等級: L5

預測適應症: 10 個

Filgrastim: From Chemotherapy-induced Neutropenia to Primary Release Disorder of Platelets

One-Sentence Summary

Filgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF) widely used to stimulate neutrophil production in chemotherapy-induced neutropenia and to mobilize hematopoietic stem cells before transplantation. The TxGNN model predicts it may be effective for Primary Release Disorder of Platelets, with no supporting literature and 10 retrieved clinical trials — none of which study Filgrastim directly for this indication. Overall evidence is classified as L4 (mechanistic/preclinical level only), and the mechanistic rationale is weak; this prediction is most likely a knowledge-graph artefact.

Quick Overview

Item	Content
Original Indication	Not available in dataset (0 registered Canadian products)
Predicted New Indication	Primary release disorder of platelets
TxGNN Prediction Score	99.998%
Evidence Level	L4
Canada Market Status	✗ Not marketed (per dataset)
Number of DINs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Filgrastim acts primarily through the G-CSF receptor (G-CSFR, CD114), activating JAK2/STAT3 and PI3K/AKT signalling cascades that drive proliferation and terminal maturation of neutrophil precursors in the bone marrow. Its established roles are reducing the duration and severity of chemotherapy-induced neutropenia and mobilising CD34⁺ progenitor cells into the peripheral blood before HSCT.

Primary release disorder of platelets refers to defective secretion of platelet α- and δ-granule contents, a process governed by RAB GTPases and the SNARE complex machinery that controls membrane fusion during degranulation. This pathway is mechanistically independent of G-CSF signalling. The only conceivable indirect link is a minor bystander effect of G-CSF on megakaryocyte differentiation outside the dominant TPO/c-Mpl axis — but this effect has never been demonstrated to influence platelet granule release in either preclinical or clinical settings.

The extremely high TxGNN score (99.998%) most likely reflects shared hematopoietic knowledge-graph nodes: neutrophils and platelets both originate in the bone marrow and are connected through common lineage and cytokine edges in the graph. This constitutes a network proximity artefact rather than a pharmacologically actionable mechanistic link. No published clinical trials or peer-reviewed literature specifically evaluating Filgrastim in platelet release disorders were found.

Clinical Trial Evidence

All retrieved trials involve Filgrastim as a stem cell mobilisation agent or post-chemotherapy supportive care drug. None were designed to study Filgrastim as a treatment for platelet release disorders. Relevance grade for all trials is C (not relevant to target indication); several are likely false-positive database matches.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01503918	Phase 2	Completed	124	Antiviral prophylaxis (valaciclovir vs valganciclovir) for CMV reactivation in immunocompetent ICU patients; Filgrastim not a study drug
NCT04047628	Phase 3	Recruiting	156	Autologous HSCT vs best available therapy for treatment-resistant relapsing multiple sclerosis; Filgrastim used only for stem cell mobilisation
NCT00354172	Phase 2	Terminated	16	Umbilical cord blood transplantation with NK cells for myeloid leukaemia (terminated early); Filgrastim as post-transplant haematopoietic support
NCT00076752	Phase 2	Completed	9	Intensified lymphodepletion followed by autologous HSCT for severe SLE; Filgrastim used for stem cell mobilisation only
NCT02646098	Phase 2	Completed	64	CD34⁺ selected vs unselected ASCT in advanced mantle cell and diffuse large B-cell lymphoma; Filgrastim used for progenitor cell harvest
NCT06859424	Phase 2	Recruiting	358	Platform trial comparing post-transplant cyclophosphamide regimens for GvHD prophylaxis in mismatched unrelated donor PBSCT
NCT05436418	Phase 1/2	Recruiting	260	Dose optimisation of post-transplant cyclophosphamide + sirolimus/MMF for GvHD prophylaxis after reduced-intensity conditioning PBSCT
NCT00245037	Phase 1/2	Completed	147	Non-myeloablative allogeneic HSCT with busulfan, fludarabine and TBI for haematologic malignancies; Filgrastim as mobilisation agent
NCT04540120	Phase 2	Terminated	49	Dapansutrile (oral NLRP3 inhibitor) for moderate COVID-19 and early cytokine release syndrome; Filgrastim is not the study drug — likely a false-positive match
NCT01335932	Phase 2	Completed	160	Ganciclovir vs placebo to reduce IL-6 and prevent CMV reactivation in immunocompetent adults with severe sepsis or trauma-associated respiratory failure; no connection to platelet disorders

Literature Evidence

Currently no related literature available.

Canada Market Information

The dataset contains 0 registered products for Filgrastim in Canada. This almost certainly reflects a data gap — Filgrastim (e.g., Neupogen®) and its approved biosimilars have long been available in many markets globally. Formal verification against the Health Canada Drug Product Database is strongly recommended before drawing any regulatory conclusions.

Safety Considerations

Please refer to the package insert for safety information.

Note: Key warnings, contraindications, and drug interaction data were not available in this Evidence Pack (data gaps DG001–DG002). Package insert review is required before any further evaluation.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a TxGNN model score of 99.998%, no direct mechanistic link has been established between G-CSF signalling and platelet α/δ-granule release pathways (RAB/SNARE machinery). All retrieved clinical trials use Filgrastim as a supportive or mobilisation agent — not as a therapy for platelet release disorders — and no relevant preclinical data or literature were identified. The high prediction score is most plausibly explained by shared hematopoietic knowledge-graph topology rather than pharmacological relevance.

To proceed, the following is needed:

Mechanistic feasibility study: In vitro or animal-model data examining whether G-CSF signalling can modulate platelet granule secretion
Safety data retrieval: Full package insert review (warnings, contraindications, drug interactions) to support any subsequent safety screening
Regulatory data reconciliation: Confirm actual Canadian DIN status via the Health Canada Drug Product Database — the current dataset reports 0 licensed products, which is inconsistent with Filgrastim’s known global approval history
Knowledge-graph audit: Investigate why TxGNN assigns a near-perfect score in the absence of a plausible mechanistic pathway; this may point to a systematic graph artefact affecting other predictions in this candidate set
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.